A study assessing the impact of the 21-gene recurrence score assay in routine clinical practice on the use of adjuvant chemotherapy in women with early stage ER-positive breast cancers showed that adjuvant chemotherapy use decreased in high-risk patients, but increased in low-risk patients. I discuss these results and highlight how this reflects more-selective administration of chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, oestrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 726–734 (2006).
Dowsett, M. et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28, 1829–1834 (2010).
Goldstein, L. J. et al. Prognostic utility of the 21-gene assay in hormone receptor–positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 26, 4063–4071 (2008).
Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55–65 (2010).
Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumour markers in breast cancer. J. Clin. Oncol. 25, 287–312 (2007).
Dinan, M. A., Mi, X., Reed, S. D., Lyman, G. H. & Curtis, L. H. Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among medicare beneficiaries with early-stage breast cancer, 2005–2009. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2015.2722.
Lo, S. S. et al. Prospective multicentre study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J. Clin. Oncol. 28, 1671–1676 (2010).
Kelly, C. M. et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116, 5161–5167 (2010).
Hassett, M. J. et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J. Clin. Oncol. 30, 2218–2226 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Pusztai, L. Chemotherapy and the recurrence score—results as expected?. Nat Rev Clin Oncol 12, 690–692 (2015). https://doi.org/10.1038/nrclinonc.2015.191
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.191
This article is cited by
-
The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients
Breast Cancer Research and Treatment (2017)
